Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00195364
NCT00195364
Completed
Not Applicable

Long-Term Safety Study of Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain

Wyeth is now a wholly owned subsidiary of Pfizer0 sites93 target enrollmentJuly 2003
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRheumatoid ArthritisInflammation
DrugsEtanercept

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rheumatoid Arthritis
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
93
Status
Completed
Last Updated
16 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU

Registry
clinicaltrials.gov
Start Date
July 2003
End Date
October 2008
Last Updated
16 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • •To have completed 0881A1-301-EU study in Spain
  • •Clinical diagnosis by ACR revised criteria of rheumatoid arthritis.

Exclusion Criteria

  • •Hypersensibility to etanercept or any of its components
  • •Significant concurrent medical disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics RegistryRheumatoid Arthritis
NCT01646385Pfizer6,393
Completed
Not Applicable
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in SpainArthritis, PsoriaticArthritis, Rheumatoid
NCT00195377Wyeth is now a wholly owned subsidiary of Pfizer1,000
Completed
Phase 3
16.0040 Ankylosing Spondylitis StudyAnkylosing Spondylitis
NCT00356356Amgen257
Completed
Phase 3
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing SpondylitisAnkylosing Spondylitis
NCT00421980Wyeth is now a wholly owned subsidiary of Pfizer84
Completed
Phase 4
Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic TreatmentsPsoriasis
NCT00967538Innovaderm Research Inc.89